Compare · AXNX vs WST
AXNX vs WST
Side-by-side comparison of Axonex AI Group Limited (AXNX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- AXNX operates in Consumer Discretionary, while WST operates in Health Care - the two are in different parts of the market.
- WST is the larger of the two at $27.34B, about 4181.9x AXNX ($6.5M).
- WST has been more active in the news (7 items in the past 4 weeks vs 2 for AXNX).
- AXNX has more recent analyst coverage (21 ratings vs 20 for WST).
- Company
- Axonex AI Group Limited
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $6.5M
- $27.34B
- 1M return
- -
- +9.93%
- 1Y return
- -
- +44.96%
- Industry
- Business Services
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 2
- 7
- Recent ratings
- 21
- 20
Axonex AI Group Limited
Axonex AI Group Limited (formerly Mint Incorporation Limited) (NASDAQ: AXNX) is a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider. Through its subsidiary, Axonex AI Limited, and its majority owned subsidiary, Rice Robotics AGI Holding Limited, the Group delivers robot models and robotics solutions, including the FLOKI Minibot M1 and micro-insurance solutions purpose-built for commercial robots. The Group also maintains its established interior design and fit-out works business. Anchored by its ongoing transformation, Axonex AI is focused on AI and robotics as its main growth driving engine.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest AXNX
- Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split
- Axonex AI Group Joins FLAIR’s Embodied AI International Applications Hub and Launches Education Humanoid TOMO
- Axonex AI Group Limited (NASDAQ: AXNX) Solidifies Transformation into an AI and Robotics-Focused Company
- CAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of Directors
- RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
- SEC Form 15-12G filed by Axonics Inc.
- SEC Form EFFECT filed by Axonics Inc.
- SEC Form 25-NSE filed by Axonics Inc.
- Director Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)
- EVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)
Latest WST
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- West to Participate in Upcoming Investor Conference
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Reports Third-Quarter 2026 Results
- SEC Form 8-K filed by West Pharmaceutical Services Inc.
- West Declares Quarterly Dividend
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea